Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cyclacel Pharmaceuti (CYCC)

6.1   -0.66 (-9.76%) 03-05 08:47
Open: 6.75 Pre. Close: 6.76
High: 6.8886 Low: 5.71
Volume: 601,016 Market Cap: 43M
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.898 - 6.954 6.954 - 6.991
Low: 5.611 - 5.664 5.664 - 5.699
Close: 6.027 - 6.113 6.113 - 6.171

Technical analysis

as of: 2021-03-05 8:09:13 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 10.79     One year: 13.34
Support: Support1: 5.71    Support2: 4.75
Resistance: Resistance1: 9.24    Resistance2: 11.42
Pivot: 7.84
Moving Average: MA(5): 6.92     MA(20): 8.14
MA(100): 5.84     MA(250): 5.35
MACD: MACD(12,26): -0.29     Signal(9): -0.03
Stochastic oscillator: %K(14,3): 13.55     %D(3): 16.72
RSI: RSI(14): 36.53
52-week: High: 19.25  Low: 3.12  Change(%): -40.2
Average Vol(K): 3-Month: 94182  10-Days: 51111

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
CYCC has closed above bottom band by 6.8%. Bollinger Bands are 62.9% wider than normal. The large width of the bands suggest high volatility as compared to CYCC's normal range. The bands have been in this wide range for 16 bars. This is a sign that the current trend might continue.

Headline News

Fri, 26 Feb 2021
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Downgraded by Zacks Investment Research to Sell - MarketBeat

Thu, 25 Feb 2021
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results - GlobeNewswire

Thu, 25 Feb 2021
Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - Yahoo Finance

Fri, 19 Feb 2021
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results - Yahoo Finance

Thu, 18 Feb 2021
Should You Buy Cyclacel Pharmaceuticals Inc (CYCC) Stock on Thursday? - InvestorsObserver

Wed, 17 Feb 2021
Do Analysts Agree on Cyclacel Pharmaceuticals Inc (CYCC) Stock's Target Price? - InvestorsObserver

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 5
Shares Float (M) 3
% Held by Insiders 2.81
% Held by Institutions 22.42
Shares Short (K) 972
Shares Short P. Month (K) 212

Stock Financials

EPS -3.120
EPS Est This Year -2.250
EPS Est Next Year -1.570
Book Value (p.s.) 5.020
Profit Margin
Operating Margin
Return on Assets (ttm) -29.0
Return on Equity (ttm) -41.5
Qtrly Rev. Growth
Gross Profit (p.s.) -0.959
Sales Per Share
EBITDA (p.s.) -2.107
Qtrly Earnings Growth
Operating Cash Flow (M) -8
Levered Free Cash Flow (M) -6

Stock Valuations

PE Ratio -1.96
PEG Ratio
Price to Book value 1.22
Price to Sales
Price to Cash Flow -3.75

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date 2016-07-31
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.